Metsera Inc., a clinical-stage biopharmaceutical company, has announced it will present new research at the 85th Scientific Sessions of the American Diabetes Association. The company will showcase its next-generation obesity portfolio, including clinical and preclinical findings from its lead program, MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist. The presentations will include clinical data from MET-097i's completed Phase 1/2 trial, alongside preclinical data on MET-233i, a monthly, ultra-long acting amylin analog. These presentations aim to highlight Metsera's scalable and differentiated approaches to treating overweight and obesity. Further details about the company's presence at the ADA meeting can be found on their website.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.